Hikmet Gülşah Tanyıldız

Dr. Hikmet Gülşah Tanyıldız

orcid

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 January 2024 in Indian Journal of Cancer
Verified
Journal Article
Open access
NTNurdan Tacyildiz
Nurdan Tacyildiz
HCHatice Mine Cakmak
Hatice Mine Cakmak
EUEmel Unal
Emel Unal
HDHandan Dincaslan
Handan Dincaslan
HTHikmet Gülşah Tanyıldız
Hikmet Gülşah Tanyıldız
IKIşınsu Kuzu
Işınsu Kuzu
Background: Long-term survivors of Hodgkin lymphoma (HL) are at risk of developing a range of late effects, with a second malignant neoplasm and cardiovascular diseases being the leading causes of death in these patients. The present study aims to evaluate the late side effects in children with HL. Materials and Methods: Out of 53 HL patients, we assessed the long-term effects of childhood HL survivors (HLSs; n = 50) diagnosed between 1998 and 2019. Patient data related to chronic health conditions, and sociodemographic characteristics were compared with their siblings ( n = 56). Results: The cumulative overall survival (OS) at 1, 5, and 10 years from diagnosis was 98.1 ± 1.9%, 93.3 ± 3.8%, and 93.3 ± 3.8%, respectively. Groups of HLSs and their siblings were matched according to age and gender. Compared with siblings, survivors had will be changed as ‘a higher frequency of nephrotoxicity ( P = 0.02)’, cardiotoxicity ( P = 0.12), thyroid dysfunction ( P = 0.001), health care service usage ( P < 0.01), limitation of physical function ( P = 0.01), and pulmonary disease ( P = 0.01). The control group of siblings had a higher incidence of marital status ( P < 0.01), parenthood ( P = 0.01), and smoking habit ( P = 0.03). Thyroid dysfunction was associated with neck radiotherapy ( P < 0.01). No secondary neoplasm was detected. In relapsed, refractory setting ( n = 10), autologous transplantation ( n = 9) is performed after a complete remission. Brentuximab vedotin with or without bendamustine and rituximab is also used in selected patients. Conclusions: Increased number of chronic health conditions and social problems point to the significance of long-term follow-up of HLSs. We are currently preparing a survivorship guideline appropriate for Turkey’s conditions. Implications for Cancer Survivors: Renal, heart, pulmonary impairment, thyroid dysfunction, limitation in physical functioning, and deterioration in social status (marriage, having children, education).

22 December 2024 in Children
Verified
Journal Article
Open access
PDF file
CBCenk Baykan
Cenk Baykan
MÇMelike Mete Çiftseven
Melike Mete Çiftseven
GKGonca Keskindemirci
Gonca Keskindemirci
OAOyku Ozboru Askan
Oyku Ozboru Askan
AKAlev Bakır Kayı
Alev Bakır Kayı
HTHikmet Gülşah Tanyıldız
Hikmet Gülşah Tanyıldız
Introduction and Aim: Propranolol is an effective treatment option for infantile hemangiomas, but there is still insufficient information about neurodevelopmental side effects of propranolol. In our study, the neurodevelopmental levels of infantile hemangioma patients receiving propranolol treatment were examined using the Bayley-III test. Method: In our single-center, cross-sectional study, patients were recruited between 1 January 2020 and 31 December 2023. In total, 40 children (n1) diagnosed with hemangioma who received propranolol treatment and 31 children (n2) who were only under observation were included. A control group of 31 healthy children (n3) matched for age and gender was also included. The demographic, clinical, perinatal, and postnatal characteristics of the total 102 children were recorded from their medical records. Neurodevelopmental levels were assessed with the Bayley-III test. The significance level was set at (p < 0.05). Results: The Bayley-III test composite and percentile scores were used to evaluate the neurodevelopmental levels. Significant differences in motor functions were found between the treated and untreated groups compared to the healthy control group (p = 0.006 and p = 0.006). However, no significant differences were found in cognitive, language, and social-emotional skills. Cognitive, language, and motor functions were associated with maternal education level, and additionally, cognitive functions were also associated with paternal education level. Conclusions: Propranolol has a relatively safer side effect profile, and therefore, it has been described as a safe agent. In our study, no significant effect of propranolol on neurodevelopment was observed. The difference in motor skills shown was mainly between the healthy control group (n3) and the treated and untreated group (n1 and n2), which led to the conclusion that the relevant difference could be due to factors other than propranolol itself.

18 February 2025 in The Turkish Journal of Pediatrics
Verified
Journal Article
Open access
PDF file
HTHikmet Gülşah Tanyıldız
Hikmet Gülşah Tanyıldız
Yasin YilmazYasin Yilmaz
Yasin Yilmaz
DDDoğa Dalay
Doğa Dalay
ŞŞŞifa Şahin
Şifa Şahin
SKSerap Karaman
Serap Karaman
DTDeniz Tuğcu
Deniz Tuğcu
Background. Infantile fibrosarcoma is a rapidly growing soft tissue tumor, often managed by surgical resection, with chemotherapy and radiotherapy as additional options. Due to the high local aggressiveness and surgical morbidity, targeted therapies like larotrectinib can enhance quality of life and preserve organs, particularly in limb-threatening cases. Here, we present three cases where larotrectinib prevented mutilating surgeries. Cases. The first patient presented antenatally with a 75 x 48 mm oral floor mass, severely narrowing the airway. Surgery was unfeasible due to invasion of vital organs, and complications arose with conventional chemotherapy. Following detection of an ETV6-NTRK3 fusion, larotrectinib was initiated, resulting in complete regression after two years. The second patient had a 42 x 37 mm right-hand tumor confirmed as infantile fibrosarcoma, for which initial treatment suggested amputation. After identifying an ETV6-NTRK3 fusion and failing to respond to chemotherapy, larotrectinib led to significant regression by year two, preserving hand function. The third patient presented with a 56 x 55 mm right foot mass at birth. Chemotherapy proved ineffective, and larotrectinib was initiated due to an ETV6-NTRK fusion signal, ultimately achieving near total regression within one year and avoiding amputation. All three cases demonstrated successful outcomes with targeted therapy. Conclusions. These cases emphasize the importance of advanced molecular studies, like next-generation sequencing, for childhood tumors and integrating research with clinical trials. tropomyosin receptor kinase inhibitor larotrectinib may offer a safe and effective alternative to chemotherapy for NTRK fusion-positive, metastatic, or unresectable tumors.

9 November 2024 in Iranian Journal of Pediatrics
Verified
Journal Article
Open access
PDF file
HTHikmet Gülşah Tanyıldız
Hikmet Gülşah Tanyıldız
Yasin YilmazYasin Yilmaz
Yasin Yilmaz
ŞŞŞifa Şahin
Şifa Şahin
SKSerap Karaman
Serap Karaman
AUAysegul Unuvar
Aysegul Unuvar
ZKZeynep Karakas
Zeynep Karakas
Background: Brain tumors are the most common solid tumors in childhood. With the help of increased clinical awareness, improvements in imaging methods, and the identification of molecular characteristics, advances have been made in both diagnosis and treatment. Objectives: In our study, we aimed to discuss the childhood brain tumor cases followed in our clinic, along with their clinical and epidemiological features and treatment outcomes. Methods: The study group comprised children younger than 18 years old who were followed in the Pediatric Hematology and Oncology Clinic of Istanbul Medical Faculty and diagnosed with a brain tumor over the past 5 years (2018 - 2023). Symptoms, age at diagnosis, treatment options (surgery, radiotherapy, chemotherapy), and side effects were reviewed retrospectively. Results: Thirty children were diagnosed with brain tumors. Of the patients, 14 (47%) were male and 16 (53%) were female. The mean age of the children was 8.8 ± 3.1 years, and the mean age at diagnosis was 65.6 ± 37.7 months. The most common symptom was vomiting (40%). The mean duration between the onset of symptoms and diagnosis was 3.8 months, with a median of 1 month. Of the patients, 60% were diagnosed with glial tumors and 40% with non-glial tumors. Gross total resection (GTR) was performed in 26% of patients, subtotal resection (STR) in 37%, and 37% of patients did not undergo surgery. Seventy-seven percent of the patients received chemotherapy, and 57% received radiotherapy. Of the patients, 57% were considered responsive to treatment (complete/partial), 30% had stable disease, and 13% had progressive disease. The overall brain tumor mortality rate in our clinic was 13%. While 73% of our 26 patients had no or mild neurological deficits, 27% had moderate to severe disabilities (gait impairment, hearing impairment, visual impairment). Conclusion: Although the sample size was limited, it may be speculated that the surgery rate was low and long-term side effects were notable. Insufficient surgical resection can affect the treatment response and increase the risk of neurological sequelae and functional impairment. Molecular profiling should be expanded, and a palliative care team should be involved as early as possible to address long-term side effects and improve the quality of life for patients.

5 June 2026 in BMC Pediatrics
Verified
Journal Article
Open access
BKBesarta Kaçabeti
Besarta Kaçabeti
RSRemziye Semerci
Remziye Semerci
PTPınar Taşpınar
Pınar Taşpınar
GEGülcan Erbaş
Gülcan Erbaş
SKSerap Karaman
Serap Karaman
HTHikmet Gülşah Tanyıldız
Hikmet Gülşah Tanyıldız
This study aims to comprehensively evaluate the efficacy and safety of Antibiotic Lock Therapy (ALT) in pediatric patients and to better clarify its role in catheter management. This retrospective single-center study was conducted between October 2021 and October 2024. Of 53 eligible patients, 47 received ALT and constituted the primary analysis population for treatment outcomes; 6 patients underwent immediate catheter removal without ALT and were excluded from the ALT efficacy analysis. Demographic, clinical, and microbiological data from all patients were collected. A total of 70 catheter-related bloodstream infection (CRBSI) episodes were identified among 47 patients, corresponding to an incidence rate of 12.79 per 1,000 catheter-days. The most frequently isolated pathogens were coagulase-negative staphylococci (CoNS), followed by gram-positive bacilli and Klebsiella spp. Antibiotic Lock Therapy (ALT) was administered to 47 patients and was successful in 70.2% of these cases (33/47) (p = 0.038). Among patients who did not receive ALT and required catheter removal, Klebsiella spp. and methicillin-resistant CoNS (MRCoNS) were the predominant organisms associated with sepsis and infection. In patients requiring catheter removal despite receiving ALT, gram-negative organisms were the most common pathogens, followed by gram-positive bacilli. Notably, infections most frequently developed between days 11 and 45 of catheter use, indicating a critical high-risk window for catheter-related infections. Catheter-related infections remain a significant clinical challenge in pediatric hematology-oncology patients. Our findings suggest that ALT was associated with catheter retention in a considerable proportion of patients; however, given the retrospective design and potential for confounding by indication, this observation should be interpreted cautiously rather than as a definitive efficacy claim. The identification of a high-risk period between days 11 and 45 may support closer monitoring and earlier intervention. Further prospective studies with standardized selection criteria are required to validate and standardize the use of ALT in this vulnerable population.

28 August 2026 in Children
Verified
Journal Article
Open access
PDF file
EIEMINE GOKNUR ISIK
EMINE GOKNUR ISIK
ŞŞŞifa Şahin
Şifa Şahin
DSDuygu Has Simsek
Duygu Has Simsek
EYEbru Yilmaz
Ebru Yilmaz
SBSema Buyukkapu Bay
Sema Buyukkapu Bay
HTHikmet Gülşah Tanyıldız
Hikmet Gülşah Tanyıldız
Background/Objectives: 18F-FDG PET/CT is increasingly used in pediatric Burkitt lymphoma (BL) for staging and treatment response assessment, but data on quantitative prognostic markers remain limited. Methods: We retrospectively evaluated 33 children with pathologically confirmed BL who underwent baseline and end-of-treatment (EOT) 18F-FDG PET/CT between 2009 and 2024. SUVmax, metabolic tumor volume (MTV), and total lesion glycolysis (TLG) were measured at baseline and EOT, and the Deauville score (DS) was assigned visually. Progression-free survival (PFS) and overall survival (OS) were estimated with the Kaplan–Meier method; receiver operating characteristic (ROC) analysis identified predictive thresholds. Results: Three-year and 5-year OS was 89.6%, and PFS was 90.1%. The percentage reduction in SUVmax from baseline to EOT (%ΔSUVmax) was the strongest predictor of survival (AUC = 0.94; optimal cutoff ≥ 73.6% reduction; sensitivity 100%, specificity 93%). Patients with an unfavorable EOT DS (4–5) had significantly lower OS than those with a favorable DS (1–3) (60.0% vs. 96.4%; log-rank p = 0.009). Baseline SUVmax, MTV, and TLG did not differ significantly by stage or splenic involvement. Given the small number of survival events (n = 3), the corresponding hazard ratios and confidence intervals should be regarded as exploratory and hypothesis-generating rather than definitive effect sizes. Conclusions: Dynamic metabolic response such as %ΔSUVmax and the EOT Deauville score are promising prognostic markers in pediatric BL. Given the small number of events, these findings warrant validation in larger, prospective cohorts.